Antimicrobial peptides are short protein fragments that act as the body's first line of defense against pathogens. Two — LL-37 and KPV — have attracted sustained research interest for their broad activity profiles. This article reviews their mechanisms and where current investigation is focused.
LL-37: A Broad-Spectrum Cathelicidin
LL-37 is the active fragment of the human cathelicidin precursor protein. It is produced by neutrophils, epithelial cells, and certain immune cells in response to infection or injury. Its name comes from its 37-amino-acid length and the two leucines at its N-terminus.
The peptide kills microbes by disrupting their cell membranes. Because bacterial, fungal, and some viral envelopes differ from human cell membranes in charge distribution, LL-37 selectively damages pathogen surfaces while sparing host cells. This mechanism is harder for microbes to develop resistance against than traditional small-molecule antibiotics.
Research has documented activity against a wide range of bacteria, including some antibiotic-resistant strains, as well as against fungi and enveloped viruses.
LL-37 Beyond Direct Antimicrobial Action
LL-37 does more than puncture microbes. It also recruits immune cells to infection sites, supports wound healing through pro-angiogenic signaling, and modulates inflammatory cytokines. This dual role — direct antimicrobial plus immune coordinator — is one reason it features in so many research programs.
Studies have examined LL-37 in contexts including chronic wounds, respiratory infection, and skin barrier function. Its expression is linked to vitamin D signaling, which has prompted research into the nutritional inputs that shape innate immune capacity.
The peptide is also studied for its role in disease states where its expression is dysregulated, including some autoimmune and inflammatory conditions.
KPV: A Small Peptide with Targeted Activity
KPV is a tripeptide — just three amino acids long — derived from the C-terminus of alpha-melanocyte stimulating hormone. Despite its short length, it has demonstrated antimicrobial and anti-inflammatory activity in research models.
Its antimicrobial mechanism is distinct from LL-37's membrane disruption. KPV appears to interfere with intracellular pathways in microbes, particularly in fungi like Candida species. The anti-inflammatory effect is mediated through melanocortin receptor signaling.
Research has focused on mucosal applications, including gut and skin models, where the combination of antimicrobial and anti-inflammatory activity is particularly relevant.
Why AMPs Matter for Infection Research
The rise of antimicrobial resistance has renewed interest in peptide-based antimicrobials. Because AMPs work through membrane disruption or pathway interference rather than enzyme inhibition, they offer different resistance profiles than conventional antibiotics.
Stability, manufacturing cost, and selective delivery remain active research challenges. Most AMPs are studied as research tools rather than as drug candidates at this stage, but the field continues to expand.
Antimicrobial peptide research is an active area, and the relationship between in vitro activity and in vivo therapeutic potential is still being mapped. All peptides discussed are intended for research use only and are not for human consumption.